News - Cephalon


Current filters:


Popular Filters

Teva to drop development of Nuvigil in bipolar 1 disorder


Israel-based leading generics company Teva Pharmaceutical Industries (NYSE: TEVA) has released disappointing…

armodafinilCephalonGenericsNeurologicalNuvigilPharmaceuticalResearchTeva Pharmaceutical Industries

Teva's EPS rockets, helped by higher sales in USA


Israel-based Teva Pharmaceutical Industries (NYSE: TEVA), the world's largest generic drugs producer…

CephalonFinancialGenericsManagementPharmaceuticalTeva Pharmaceutical Industries

Mylan settles Provigil litigation with Teva


US generic major Mylan (Nasdaq: MYL) says that its subsidiary Mylan Pharmaceuticals has resolved all…

CephalonFinancialGenericsLegalMylan LaboratoriesNeurologicalNorth AmericaProvigilTeva Pharmaceutical Industries

Israel'sTeva beats expectations with 40% leap in profit


Israel-headquartered Teva Pharmaceutical Industries (Nasdaq: TEVA) has reported a robust set of first-quarter…

CephalonFinancialGenericsPharmaceuticalTeva Pharmaceutical Industries

Opportunities for Pharma in narcolepsy


The narcolepsy therapeutics developmental pipeline is weak, with only six molecules in development, providing…

BioprojectCephalonGenericsMarkets & MarketingNeurologicalNuvigilPharmaceuticalProvigilResearchTeva Pharmaceutical IndustriesUCBXyrem

Teva Pharma strong sales growth helped by acquisitions


Israel-headquartered Teva Pharmaceutical Industries (Nasdaq: TEVA) reported fourth-quarter 2011 results…

CephalonFinancialGenericsPharmaceuticalTeva Pharmaceutical Industries

Acino buys more Cephalon/Mepha businesses


Swiss branded and generic drugmaker Acino Pharma (SIX: ACIN) and Israel’s Teva Pharmaceutical Industries…

Acino PharmaCephalonGenericsMephaMergers & AcquisitionsTeva Pharmaceutical Industries

Acino pays 80 million euros for Cephalon’s Middle East and African business


Switzerland-based generic and branded drugmaker Acino (SIX: ACIN) says it has reached agreement to acquire…

Acino PharmaCephalonGenericsMergers & AcquisitionsPharmaceuticalRest of the WorldTeva Pharmaceutical Industries

Teva gets EU clearance for Cephalon acquisition; negative review on Azilect


Following US antitrust clearance last week, Israel-based Teva Pharmaceutical Industries (Nasdaq: TEVA)…

AzilectCephalonMergers & AcquisitionsNeurologicalPharmaceuticalRegulationTeva Pharmaceutical Industries

Cephalon reports disappointing 2nd-qtr 2011 results, ahead of completion of acquisition by Teva


US biotech firm Cephalon (Nasdaq: CEPH), the subject of a $6.8 billion takeover deal from Israeli generics…

BiotechnologyCephalonFinancialTeva Pharmaceutical Industries

Cephalon 1st-qtr 2011 sales leap 28% but below consensus forecasts


US drugmaker Cephalon (Nasdaq: CEPH), which earlier this week agreed to be acquired by Israel’s…


European Commission opens investigation against Cephalon and Teva


The European Commission has opened a formal antitrust investigation to assess whether an agreement between…

CephalonEuropeGenericsLegalTeva Pharmaceutical Industries

Back to top